Search clinical trials for: Fosaprepitant

Total 82 results

Sun Yat-sen University

Completed

Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Philip Philip
National Cancer Institute (NCI)

Completed

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Gastrointestinal Cancer | Nausea Post Chemotherapy

United States
Stanford University

Completed

Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia

Postoperative Nausea

United States
Multicenter Clinical Study Group of Osaka, Colorectal...

Completed

Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial

Colorectal Cancer

Japan
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

Unspecified Adult Solid Tumor, Protocol Specific | Breakthrough Nausea and Vomiting

United States
Xijing Hospital

Recruiting

Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV. (COSEFDIP)

Neoplasms

China
Gynecologic Oncology Associates
Merck Sharp & Dohme LLC

Completed

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Ovarian Cancer | Uterine Cancer

United States
Ajeet Gajra
Merck Sharp & Dohme LLC

Unknown

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

Nausea | Vomiting | Non-small Cell Lung Cancer | Emesis

United States
Samsung Medical Center

Enrolling by invitation

Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant as PONV Prevention

Postoperative Nausea and Vomiting | Laparoscopy | Gynecologic Surgical Procedures

Korea, Republic of
Sun Yat-sen University
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study (OFFER)

Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy

China
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

Chemotherapy-Induced Nausea and Vomiting
Montefiore Medical Center

Not yet recruiting

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting: A Randomized Control Trial (AFTR NV RCT)

Nausea | Vomiting | Nausea and Vomiting

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

Breast Cancer | Nausea | Vomiting

United States
Merck Sharp & Dohme LLC

Completed

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)

Chemotherapy-induced Nausea and Vomiting
Qilu Hospital of Shandong University

Not yet recruiting

Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic Surgery

Thoracic Diseases | Postoperative Nausea and Vomiting | Anesthesia Complication
Merck Sharp & Dohme LLC

Terminated

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)

Chemotherapy-Induced Nausea and Vomiting
Shanghai Children's Medical Center

Not yet recruiting

Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients

Chemotherapy Induced Nausea and Vomiting | Pediatric Cancer Patients

China
Merck Sharp & Dohme LLC

Terminated

Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) (EVADE)

Nausea | Vomiting
Odense University Hospital
Helsinn Healthcare SA

Completed

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin (GAND-emesis)

Genital Neoplasms, Female | Nausea | Vomiting

Norway, Denmark, Germany, Australia
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Chemotherapy-Induced Nausea and Vomiting (CINV)
University of Pennsylvania
National Institute of Mental Health (NIMH)

Completed

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals

HIV Infections

United States
Albert Einstein College of Medicine
Jacobi Medical Center

Terminated

Low Dose Aprepitant for Patients Receiving Carboplatin

Chemotherapy-induced Nausea and Vomiting

United States
Merck Sharp & Dohme LLC

Completed

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Chemotherapy-induced Nausea and Vomiting

United States, Greece, Hungary, Lithuania, Netherlands, Peru, Poland, Russian Federation, United Kingdom
Arun Gupta
Cambridge University Hospitals NHS Foundation Trust

Withdrawn

Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury (NK1)

Traumatic Brain Injury
University of Washington
National Institutes of Health (NIH)

Completed

Flumazenil Reversal of Oral Triazolam

Dental Anxiety

United States
Henan Cancer Hospital

Completed

Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer

Chemotherapy-induced Nausea and Vomiting

China
University of Pennsylvania
National Institute of Mental Health (NIMH)

Completed

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose

HIV Infection

United States
The Hospital for Sick Children

Terminated

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents

Nausea | Vomiting | Chemotherapy

Canada
Ono Pharmaceutical Co. Ltd

Completed

ONO-7436 Phase II Study in Japan

Malignant Tumor

Japan
LEO Pharma

Completed

Topical Aprepitant in Prurigo Patients (iTAPP)

Pruritus

Germany
St. Louis University
Merck Sharp & Dohme LLC

Terminated

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma (HDIL2/Emend)

Chemotherapy-induced Nausea and Vomiting

United States
University of Pennsylvania

Completed

Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients (PONV)

Nausea | Vomiting

United States
Sun Yat-sen University

Completed

Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients

Pediatric Cancer

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

China
Dartmouth-Hitchcock Medical Center

Completed

Differentiating the Effects of Substance P and Beta-endorphin

Chronic Obstructive Pulmonary Disease

United States
The Affiliated Hospital of Qingdao University

Not yet recruiting

Comparative Pharmacokinetic Study of Aprepitant Injection in Humans

Healthy
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

Chemotherapy-induced Nausea and Vomiting
Sixth Affiliated Hospital, Sun Yat-sen University

Completed

Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery

C.Surgical Procedure; Gastrointestinal

China
Shanghai Children's Medical Center

Not yet recruiting

Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs

Chemotherapy Induced Nausea and Vomiting Pediatric Cancer Patients

China
The Hospital for Sick Children

Completed

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers

Chemotherapy-induced Nausea and Vomiting

Canada
Merck Sharp & Dohme LLC

Completed

Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017) (EASE)

Chemotherapy-Induced Nausea and Vomiting (CINV)
IWK Health Centre

Not yet recruiting

Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery

Anesthesia | Spinal Fusion | Nausea and Vomiting, Postoperative
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Breast Cancer | Chemotherapy-induced Nausea and Vomiting

China
University of Virginia
National Institute on Drug Abuse (NIDA)

Completed

Medications Development for the Treatment of Cannabis Related Disorders (MTC)

Cannabis Dependence | Nicotine Dependence | Marijuana Dependence | Cannabis Abuse | Nicotine Withdrawal

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Malignant Neoplasm

United States, Guam
University of Washington
National Cancer Institute (NCI)

Terminated

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Nausea and Vomiting | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Nasopharynx | Stage III Squamous Cell Carcinoma of the Oropharynx and other conditions

United States
University Hospital, Rouen

Completed

Effects of Substance P Antagonists on Adrenal Secretion (APHOS)

Healthy Volunteers

France
Merck Sharp & Dohme LLC

Completed

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Chemotherapy-Induced Nausea and Vomiting (CINV)
Merck Sharp & Dohme LLC

Completed

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

Chemotherapy-Induced Nausea and Vomiting
Hospital Federal de Bonsucesso

Unknown

PALONOSETRON X FOSAPREPITANT IN PONV

Nausea and Vomiting, Postoperative

Brazil

Search clinical trials for: Fosaprepitant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations